Does overeating on tirzepatide mean my dose is too high
Before & After: Setting Realistic Tirzepatide Expectations The ideal candidate for tirzepatide therapy is typically someone with a BMI of 30 or higher, or a BMI of 27 or higher accompanied by weight-related comorbidities such as hypertension, high cholesterol, insulin resistance, or type 2 diabetes
This pathway, catalyzed by betaine-homocysteine methyltransferase, mainly occurs in the liver
these variants seem to be inherited through recessive inheritance in the case of PFIC, while less severe diseases like ICP or LPAC are likely to be inherited as autosomal dominant variations
So Lillys obesity strategy looks less like a single-product story and more like a portfolio strategy: multiple mechanisms, multiple formats, and multiple clinical questions